Defined medicine
Bremelanotide medicine evidence
- Known formulation and manufacturing controls
- Phase 3 trials in a defined population
- Narrow US indication
- Labelled contraindications and adverse reactions
- Pharmacovigilance route
Evidence profile · C-021
PT-141 and bremelanotide: medicine evidence versus a research vial
A molecule name does not make two products equivalent. US medicine evidence is tied to a defined formulation, population, indication and controls.
Bremelanotide has controlled human evidence and a narrow US marketing authorisation for acquired, generalised hypoactive sexual desire disorder in premenopausal women. That evidence does not establish a research-labelled PT-141 vial, use in men, sexual performance, fertility or wider wellbeing claims.
The authorised medicine has a specified formulation, manufacturing standard, contraindications and post-market safety route. An online vial may use the same molecule name, but its identity, amount, impurities, sterility and clinical equivalence remain separate questions. No UK marketing authorisation was identified for this indication.
Object definition
The authorised medicine and the research vial are not one object
Evidence transfers only when the relevant product, formulation, route and use match.
Unverified product
Research-labelled PT-141 vial
- Identity may need independent confirmation
- Stated amount is not self-proving
- Impurity and aggregation profile may differ
- Sterility and endotoxin require separate tests
- No automatic clinical equivalence
Claim-level evidence
What the trials support
The pivotal programme studied a specific diagnosis, population and product.
Two randomised, double-blind, placebo-controlled phase 3 trials assessed bremelanotide in premenopausal women with acquired, generalised hypoactive sexual desire disorder. The programme found statistically significant changes in sexual desire and distress measures. The FDA authorised Vyleesi in 2019 for that narrow use.
The label excludes cases caused by another medical or psychiatric condition, relationship problems or medication effects. It also states that the medicine is not indicated for postmenopausal women or men and not to enhance sexual performance. Those limits belong in the headline conclusion, not in small print.
Known risks
What the medicine label says about safety
Known medicine risks remain relevant, while an unverified vial adds further uncertainty.
Blood pressure
The US label warns of transient increases in blood pressure and reductions in heart rate. It contraindicates use in uncontrolled hypertension or known cardiovascular disease.
Nausea and other reactions
Nausea was the most common adverse reaction in trials. Flushing, headache, vomiting, injection-site reactions, fatigue and dizziness also occurred.
Skin pigmentation
Focal hyperpigmentation can occur and may persist. The label notes greater likelihood with darker skin and repeated exposure.
Product uncertainty
A research vial adds unknown identity, quantity, impurity, sterility and handling risks beyond the medicine-label evidence.
Decision table
Which common claims cross the evidence boundary
| Claim | Assessment | Reason |
|---|---|---|
| Treats acquired, generalised HSDD in premenopausal women | Narrowly supported for the authorised US medicine | Controlled trials and FDA authorisation; diagnosis and exclusions matter |
| Boosts libido in anyone | Not established | Population and indication exceed the evidence |
| Treats erectile dysfunction in men | Not an authorised use; evidence does not support a general claim | The label specifically excludes use in men |
| Improves fertility | Unsupported | Desire outcomes do not establish reproductive outcomes |
| A PT-141 vial is equivalent to Vyleesi | Unsupported without product-specific evidence | A shared name does not prove formulation, identity, quantity, sterility or bioequivalence |
Decision boundary
What remains unknown
The medicine evidence resolves a narrow question. It leaves broad consumer and vial questions open.
- Whether an online vial contains bremelanotide at the labelled amount.
- Whether the vial meets injectable impurity, sterility and endotoxin standards.
- Whether outcomes extend to men, postmenopausal women or people without diagnosed HSDD.
- Whether a non-authorised formulation matches the pharmacokinetics and safety of the studied product.
- The full long-term risk profile outside the authorised population and use.
- The current UK classification of a particular product and presentation.
Evidence appraisal
How to apply the bremelanotide trials without overextending them
The phase 3 programme answers a defined medicine question. Five filters determine whether that answer fits a new claim.
Population: diagnosed HSDD, not a universal libido claim
The trials enrolled premenopausal women with acquired, generalised hypoactive sexual desire disorder. “Acquired” means the problem developed after a period without it. “Generalised” means it was not limited to a particular situation or partner. The diagnosis also requires clinically significant distress. A person seeking performance enhancement, a man with erectile dysfunction or someone with low desire caused by another condition does not match that study population.
The label excludes symptoms explained by a co-existing medical or psychiatric condition, relationship difficulty or medicine effect. These exclusions matter because sexual symptoms may point to cardiovascular, endocrine, neurological, pain, mental-health or medicine-related causes. Treating the product name as the starting diagnosis can delay a more relevant assessment.
Intervention: a controlled medicine formulation
Trial participants received the studied formulation within a regulated development programme. Manufacturing controls, release specifications, stability, packaging and adverse-event procedures defined that product. A seller can print “PT-141” or “bremelanotide” on a vial without establishing those attributes. Matching the active molecule would address only one part of equivalence.
Quantity and impurities can change exposure. Aggregates and peptide-related impurities may create risks not represented by the medicine label. For an injectable product, sterility, endotoxin and container integrity need dedicated evidence. A chromatographic area percentage cannot stand in for these controls.
Comparator and outcomes: statistically significant does not mean complete relief
The pivotal trials compared bremelanotide with placebo and assessed validated sexual-desire and distress measures. A group-level difference shows an average trial effect under the study conditions. It does not guarantee benefit for an individual, settle every dimension of sexual function or establish relationship outcomes. Absolute changes, responder definitions, discontinuations and adverse reactions belong beside the headline result.
The label notes that nausea was common and that blood pressure can rise transiently while heart rate falls. Uncontrolled hypertension and known cardiovascular disease are contraindications. Focal skin darkening may persist. These are not generic warnings added to balance positive copy; they form part of the medicine evidence and affect the risk-benefit decision.
Jurisdiction: US authorisation is not UK authorisation
The FDA decision establishes a US marketing authorisation for the specified product and indication. It does not create a UK marketing authorisation. UK status must be checked in the current MHRA products database and against the product presentation. An online listing aimed at UK consumers may raise medicine-supply questions even when it carries a research disclaimer.
Time: safety knowledge can change
Pre-authorisation trials estimate common short-term effects in selected participants. Post-market surveillance can reveal uncommon or delayed patterns. A research vial may not feed into the same pharmacovigilance system, and uncertain sales volume prevents a reliable adverse-event rate. Few reports therefore cannot establish low risk.
| Question | Required match | If it does not match |
|---|---|---|
| Who was studied? | Premenopausal women with acquired, generalised HSDD and specified exclusions | Do not transfer the efficacy conclusion |
| What product was studied? | The authorised formulation with regulated manufacturing controls | Treat identity, quality and exposure as unverified |
| What outcome was measured? | Validated desire and distress outcomes | Do not convert to erection, fertility or performance claims |
| Which jurisdiction decided? | United States FDA | Check current UK authorisation and supply rules separately |
| What safety system applies? | Labelled contraindications and pharmacovigilance | Do not infer safety from sparse seller or user reports |
Product evidence
What would be needed to compare a PT-141 vial with the studied medicine
First, the active substance would need an unambiguous identity test that distinguishes bremelanotide from related peptides, truncations and substitutions. A mass match alone may not establish sequence, stereochemistry or all modifications. Quantity would need a calibrated method and a stated basis, including any salt, counterion and water content that affects the labelled mass.
Second, the impurity profile would need route-appropriate limits and methods. Peptide synthesis can leave deletion sequences, residual reagents and other related substances. Oxidation, hydrolysis or aggregation may develop during storage. A single area-purity number does not describe every impurity or its biological significance.
Third, an injectable comparison requires microbiological controls. Sterility, bacterial endotoxin, visible and subvisible particles, container integrity and stability answer distinct questions. Testing one selected vial cannot prove uniformity across a seller batch unless the sampling plan supports that inference.
Fourth, matching active-substance tests would still not establish pharmaceutical equivalence. Excipients, concentration, pH, delivery system and storage affect exposure and tolerability. Bioequivalence or therapeutic equivalence requires appropriate comparative evidence, not a certificate that names the same molecule.
Finally, a product report cannot reproduce the medicine system. The authorised product carries labelled contraindications, manufacturing oversight, traceable distribution and pharmacovigilance. A research-labelled vial may not offer a reliable route for recalls or adverse-event rate estimates. These differences explain why molecule evidence and product evidence remain separate even when both records are technically credible.
Chemical match
Identity, amount, related substances, aggregates and stability.
Injectable quality
Sterility, endotoxin, particles and container controls.
Clinical match
Formulation, exposure, population, indication, outcomes and safety surveillance.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| FDA: Vyleesi prescribing information | The authorised population, indication, exclusions, contraindications and adverse reactions. | It does not establish any research-labelled PT-141 vial or UK authorisation. | |
| FDA: Vyleesi approval letter | US marketing authorisation for the specified medicine and indication. | US authorisation does not confer UK marketing authorisation. | |
| Obstetrics & Gynecology: phase 3 trials | Randomised phase 3 efficacy and safety findings in premenopausal women with HSDD. | The trials do not establish broad libido, male sexual-health or fertility claims. | |
| MHRA products database | The route to check current UK marketing authorisations. | A name search alone cannot classify every online presentation. | |
| MHRA: borderline products and GN8 | UK presentation and function tests for medicinal products. | It does not verify vial contents or clinical equivalence. |
Continue the investigation
Read the connected evidence
- the sexual-health claims examinedCompare bremelanotide with fertility and reproductive-axis claims.
- whether the vial contains the authorised moleculeSee which methods address identity, amount, impurities and sterility.
- known versus unknown risksSeparate labelled adverse reactions from product uncertainty.
- the evidence libraryRead claim-level verdicts without transferring one indication to another.
Quick answers
Frequently asked questions
Are PT-141 and bremelanotide the same molecule?
PT-141 is a common name for bremelanotide, but products bearing that name are not automatically equivalent. Formulation, manufacturing controls and verified contents matter.
What is bremelanotide authorised for?
The US-authorised medicine is for acquired, generalised hypoactive sexual desire disorder in premenopausal women when specified exclusions do not explain the condition.
Is bremelanotide authorised for men?
No. The US label states that it is not indicated for men or to enhance sexual performance.
Is PT-141 authorised in the UK?
No UK marketing authorisation was identified for bremelanotide for this indication when this draft was checked. Confirm current status in the MHRA products database.
What are the main known risks?
The medicine label highlights transient blood-pressure increases, heart-rate reductions, nausea, flushing, headache, vomiting, injection-site reactions and possible focal hyperpigmentation.
Does a certificate make a PT-141 vial equivalent to Vyleesi?
No. A certificate may report selected tests, but equivalence requires much more than a shared molecule name or one purity result.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item C-021, PT-141 and bremelanotide was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.